Heart failure market to quadruple in ten years to $16 billion
pharmafile | July 6, 2017 | News story | Sales and Marketing | GlobalData, Novartis, heart failure
New research from intelligence firm GlobalData has indicated that the market for heart failure drugs is forecast to expand by more than four times in a single decade, growing from $3.7 billion in 2016 to $16.1 billion in 2026 across the seven key markets: US, UK, France, Germany, Spain, Italy and Japan – a compound annual growth rate of 15.7%.
Key drivers of this growth include an anticipated surge in use of Novartis’ heart failure drug Entresto (sacubritil/valsartan). The treatment achieved FDA approval in 2015 and NICE approval the following year, and despite initial sales being lower than expected, it is thought that it could go on to make big sales for Novartis.
The launch of other chronic heart failure drugs is also thought to have a considerable impact on the market, particularly Amgen and Cytokinetics’ omecamtiv mecarbil. However, beyond this, the disease’s ever-growing global presence is foremost among the reasons propelling the sector’s growth.
“Over the past two decades, chronic heart failure therapies have demonstrated success in slowing the progression of the disease and in reducing both mortality and morbidity in large-scale clinical trials,” explained Elizabeth Hamson, Healthcare Analyst for GlobalData. “However, these successes have been limited to heart failure with reduced ejection fraction (HF-REF), showing only moderate benefits in heart failure with preserved ejection fraction (HF-PEF). Despite the lack of strong clinical evidence, guideline-recommended HF-REF therapies are widely used to treat HF-PEF.
“Based on this, drug developers have historically only targeted HF-REF in their drug strategies,” she explained. “With HF-PEF on the rise, however, this patient cohort represents a lucrative opportunity for pharmaceutical companies such as Novartis, which recently launched its first-in-class angiotensin receptor-neprilysin inhibitor Entresto in the US for HF-REF, and is currently conducting late-stage trials of the drug in HF-PEF patients.”
Matt Fellows
Related Content
PeptiDream and Novartis extend peptide discovery collaboration
PeptiDream has announced the expansion of its peptide discovery collaboration with Novartis Pharma AG.
Novartis shares new data about Fabhalta for IgAN treatment
Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …
FDA approves Eko Health’s AI for heart failure detection
Eko Health has announced that the US Food and Drug Administration (FDA) has approved its …
